Lv32
300 积分 2024-12-15 加入
Discovery and development of SIM0709, a novel bi-specific antibody targeting TL1A and IL23p19 for the treatment of IBD and beyond 4676
16小时前
已完结
Shedding LIGHT and TL1A on Pulmonary Fibrosis
2个月前
已关闭
A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus
2个月前
已完结
Active learning framework leveraging transcriptomics identifies modulators of disease phenotypes
2个月前
已完结
Ms4a7 expression in cDC1s determines cross-presentation and antitumor immunity
2个月前
已完结
Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
2个月前
已完结
Myelin injury precedes axonal injury and symptomatic onset in multiple sclerosis
2个月前
已完结
Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial
3个月前
已完结
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy
3个月前
已完结
PIT565, a First-in-Class Anti-CD19, Anti-CD3, Anti-CD2 Trispecific Antibody for the Treatment of B Cell Malignancies
3个月前
已完结
皖公网安备34019202002308
